The TIDE score is a surrogate biomarker that can be utilized to forecast the likelihood of NSCLC patients responding to immune checkpoint blockade therapies, such as anti‐PD1 and anti‐CTLA4. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.